Showing 111-120 of 325 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs | University of Massachusetts Medical School | Michael Brehm | Cures | 01-November-2024 to 31-October-2027 | $825.000,00 |
| Identifying pharmaceuticals for enhancing metabolic maturity of stem cell derived islets | Regents of the University of Michigan | Lonnie Shea | Cures | 01-December-2024 to 30-November-2027 | $1.125.000,00 |
| Cognitive behavioral therapy to address anxiety in pre symptomatic type 1 diabetes | Regents of the University of Colorado | Holly O'Donnell | Cures | 01-July-2024 to 30-June-2027 | $600.000,00 |
| Long-read approaches to identify coding, non-coding, and structural variation that contributes to T1D risk | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-September-2024 to 28-February-2026 | $150.000,00 |
| New lipid biomarker to predict early risk for Type 1 diabetes | Beth Israel Deaconess Medical Center Inc | Barbara Kahn | Cures | 01-September-2024 to 31-August-2027 | $899.997,53 |
| University of Michigan and OHSU Breakthrough T1D Cardio-Renal Center of Excellence : Accelerating Breakthrough Targeted New Therapies for Cardio-Renal Complications for People with T1D | Regents of the University of Michigan | Matthias Kretzler | Improving Lives | 01-May-2025 to 30-April-2028 | $2.842.434,27 |
| Advanced CGM analyses for longitudinal monitoring of early-stage Type 1 Diabetes | Regents of the University of Colorado | Andrea Steck | Cures | 01-October-2024 to 30-September-2027 | $900.000,00 |
| CGM-Derived Glucose Dynamic Index as Diagnostic Marker for Progression to Type 1 Diabetes | Trustees of Indiana University | Viral Shah | Cures | 01-November-2024 to 31-October-2027 | $900.000,00 |
| Targeted mRNA LNP strategies to modulate lymphocyte migration and Treg function for T1D immunotherapy | Trustees of the University of Pennsylvania | Michael Betts | Cures | 01-September-2024 to 31-August-2027 | $900.000,00 |
| S1P transport inhibitors for prevention of T1D | Rector & Visitors of the University of Virginia | Kevin Lynch | Cures | 01-October-2024 to 30-September-2026 | $520.627,00 |